LLY (Eli Lilly and Company) Stock Market Reviews

crown

search

Read and share opinions on LLY (Eli Lilly and Company) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

LLY

Eli Lilly and Company

clarify Drug Manufacturers - General

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Dow Jones Futures: Market Near Highs As New Year Looms; Eli Lilly, Shopify Forge Buy Points
Dec 31, 2025
Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market
Dec 30, 2025
Can Amgen's MariTide Take on Leaders in the Obesity Space?
Dec 30, 2025
Novo and Lilly cut prices of weight-loss drugs in China
Dec 30, 2025
Joel Habener, Whose Research Helped Develop Weight-Loss Drugs, Dies at 88
Dec 29, 2025
Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026
Dec 28, 2025
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026
Dec 26, 2025

Reviews

LLY News

Novo and Lilly cut prices of weight-loss drugs in China
<body><p>STORY: Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China.</p><p>Novo did not give details on the new prices.</p><p>But media outlet Yicai reported earlier that list prices for the two highest dosages of Wegovy were cut by 48% in some Chinese provinces.</p><p>The Danish drug maker confirmed a price adjustment to Reuters in a statement.</p><p>Lilly did not immediately respond to a request for comment.</p><p>According to a WeChat account for a hospital in the eastern city of Nanjing posted late last week, prices for Lilly's Mounjaro would also decrease from January 1st.</p><p>Over 65% of China's population of around 1.4 billion could be overweight or obese by 2030.</p><p>And both drugmakers are competing with rivals in the rapidly growing market.</p><p>They also face challenges after Novo's patent on Wegovy's active ingredient semaglutide expires in 2026 in China and other important markets.</p><p>Novo slashed Wegovy prices by up to 37% in India last month, as it seeks to gain ground in another fast-emerging market.</p><p>Both Novo and Eli Lilly also agreed to cut U.S. prices in November.</p></body>
Dec 30, 2025
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.
Dec 29, 2025
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.
Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now.
Dec 29, 2025
UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026
Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.
Dec 29, 2025
Joel Habener, Whose Research Helped Develop Weight-Loss Drugs, Dies at 88
Joel F. Habener, a Harvard University academic whose research paved the way for revolutionary weight-loss drugs Ozempic, Mounjaro and others, which analysts forecast will be the biggest blockbusters in pharmaceutical history, died Sunday in Newton, Mass. He was 88. Eileen Martin, a friend of Habener’s, said he died peacefully at home. Habener led research that discovered a hormone dubbed GLP-1.
Dec 29, 2025
Novo Nordisk just pulled off something nobody saw coming
Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again. Novo has a new weapon in its obesity portfolio with the once-daily Wegovy tablet, which is the first oral GLP-1 medication approved in the U.S. for weight loss. This comes at a time when ...
Dec 28, 2025
5 Healthcare Themes for Investors to Watch in 2026
Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.
Dec 28, 2025
Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026
Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts. These stocks provide rising income and often deliver superior total returns through compounding. Research from Hartford Funds, using Ned Davis Research data from 1973 to 2025, shows companies that grew or initiated dividends in the S&P 500 achieved higher ... Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026
Dec 28, 2025
3 Drug Stocks to Buy at a Discount
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.
Dec 27, 2025
Here Are My Top 3 Growth Stocks to Buy Now
These profitable businesses have plenty of room left to run.
Dec 27, 2025
The Best Stocks to Invest $50,000 in Right Now
If you're investing for the long run, there are a myriad of companies begging to be bought.
Dec 27, 2025
Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access
US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.
Dec 26, 2025
GLP-1 Drugs Quietly Reshape How Americans Shop for Food, Study Finds
New research shows GLP-1 medications are changing food spending patterns well beyond weight loss
Dec 26, 2025
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Dec 26, 2025
Sector Update: Health Care Stocks Lower in Friday Afternoon Trading
Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H
Dec 26, 2025
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company ("Lilly").
Dec 26, 2025
Sector Rotation: 2 Smart Money Moves for 2026
Investors are rotating capital into communication services and healthcare stocks as falling interest rates create new opportunities for growth and income.
Dec 26, 2025
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026
Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large potential catalysts on the horizon.
Dec 26, 2025
Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says
Eli Lilly (LLY) and Novo Nordisk (NVO) are racing to cement their lead in India’s obesity drug market before cheaper generic version enter stores in March, Rishika Sadam of Reuters reports. Novo’s strategy focuses on price cuts and accelerated launches while Lilly’s products benefitted from entering the market early. Both companies have outreached to doctors, advertised heavily, provided incentives to patients, and entered distribution deals with local drugmakers, doctors, analysis, and others i
Dec 25, 2025
Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program
In recent days, analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking Therapeutics after competitor Eli Lilly’s successful Phase 3 oral obesity study appeared to support Viking’s own oral obesity drug program. This external validation of Viking’s lead candidate VK2735 has sharpened investor focus on the company’s potential role in the rapidly evolving obesity treatment market. We’ll now examine how this strengthened confidence in VK2735’s commercial prospects...
Dec 25, 2025
Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie
Dec 25, 2025
Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?
It's a two-horse race right now, sort of.
Dec 25, 2025
As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?
As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?
Dec 25, 2025
How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors
Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and disclosed a new collaboration with Eli Lilly to test zugo-cel alongside pirtobrutinib. By pairing strong initial response rates and a favorable safety profile with Lilly’s kinase inhibitor, CRISPR Therapeutics is broadening zugo-cel’s potential role across both oncology and autoimmune...
Dec 24, 2025
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?
NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.
Dec 24, 2025
Novo’s Wegovy pill is planned to enter U.S. self-pay channels, Reuters says
Novo Nordisk’s (NVO) newly approved version of Wegovy is planned to go straight to U.S. self-pay channels in early January, Maggie Fick of Reuters reports. As part of the company’s deal with the Trump administration in November, Novo and Lilly (LLY) agreed to sell starter doses of their weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients as well as cash-paying customers without insurance coverage. The pill will serve as a test case for the cash-paying consumer market.Claim
Dec 24, 2025
Weight-loss pill approval spurs food industry overhaul
<body><p>STORY: Packaged food makers and fast-food chains could be forced to overhaul more of their products next year as a newly-approved weight-loss pill hits the market.</p><p>That's according to food industry analysts who spoke to Reuters.</p><p>The U.S. Food and Drug Administration approved Novo Nordisk's Wegovy GLP-1 pill on Monday, sending shares of food companies down on Tuesday.</p><p>Eli Lilly's rival medication is expected to gain approval from regulators next year.</p><p>Up until now, GLP-1 medications have only been available in injectible form.</p><p>More Americans are expected to try the drugs as a pill rather than as a shot because the medication will be cheaper and many patients are hesitant to inject themselves.</p><p>Food companies including Conagra Brands and Nestle are already dealing with shifts in consumer tastes toward higher protein and smaller portions due to the popularity of weight-loss injections. </p><p>Earlier this year, Conagra started labeling some of its Healthy Choice frozen meals with high protein and fiber as, quote, "GLP-1 friendly." </p><p>Nestle, the world's biggest food company, has also introduced new frozen meals that cater specifically to GLP-1 users, called Vital Pursuit. </p><p>Some 40% of American adults are obese, U.S. government data shows, and around 12% of adults say they currently take GLP-1 drugs, according to a poll published last month by health policy research organization KFF.</p></body>
Dec 24, 2025
3 Stocks That Investors Might Be Undervaluing By Up To 32.3%
As the S&P 500 closes at a record high, buoyed by stronger-than-expected economic growth and a tech stock rally, investors are keenly observing which sectors might lead the market next year. Amidst this optimistic environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for those looking to capitalize on market inefficiencies.
Dec 24, 2025
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare and Medicaid Services (CMS) and pharmaceutical partners,...
Dec 24, 2025
The U.S. Offered Putin’s Closest Ally Sanctions Relief—and a Weight-Loss Drug
Engaging one of the world’s most repressive regimes, Trump envoy bonded with Belarusian dictator over Zepbound and obtained the release of hundreds of prisoners.
Dec 24, 2025
5 Big Drug Stocks That May Continue to Outperform in 2026
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Dec 23, 2025
Novo's GLP-1 pill gets approved, Trump Media stock pulls back
Yahoo Finance Executive Editor Brian Sozzi tracks some of Tuesday's trending tickers, including Novo Nordisk (NVO), Eli Lilly (LLY), D-Wave Quantum (QBTS), and Trump Media & Technology Group (DJT, DJTWW). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
Dec 23, 2025
Novo Nordisk Jumps 7% After FDA Approves First Ever GLP-1 Pill
Approval gives Danish drugmaker early lead over Eli Lilly in obesity treatment race.
Dec 23, 2025
Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer answered questions about. Inquiring if their portfolio is diversified, a caller highlighted that their top five holdings are LLY, SLG, MSFT, CVX, and TSM. Cramer said: “Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for […]
Dec 23, 2025
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
Dec 23, 2025
Why Eli Lilly Shares Are Down On Tuesday
Eli Lilly Faces Pressure as Novo's Daily Pill Hits the Market;'
Dec 23, 2025
Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill
Investing.com -- Shares in Novo Nordisk jumped Tuesday after the company won U.S. approval for its GLP-1 weight-loss pill, marking the first time such a treatment has been cleared in oral form.
Dec 23, 2025
GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market is Expected to Grow Significantly
The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at a CAGR of 13.0%. Driven by expanding indications, the market sees robust demand amid rising chronic conditions like obesity and diabetes. Patented products dominated the market in 2024, while biosimilars are projected to rise post-2026, following patent expiry. In 2024, home-care settings led the market by end user due to rising self-administration trends. The US helmed t
Dec 23, 2025
Novo Nordisk Loses Weight-Loss Lead as Lilly Gains Ground
Competition from Eli Lilly, copycat drugs, and pricing pressure is reshaping Novo's outlook despite an upcoming oral Wegovy launch.
Dec 23, 2025
Stock futures, gold record high, FDA approves GLP-1 pill: 3 Things
US stock futures (ES=F, NQ=F, YM=F) are moving lower after the S&P 500 (^GSPC) closed higher on Monday, notching its third straight day of gains. Gold prices (GC=F) continue to climb to record highs this week, now ascending above $4,500 per ounce. The US Food and Drug Administration (FDA) has approved the first GLP-1 weight-loss pill from Novo Nordisk (NVO), with Eli Lilly (LLY) expected to soon reveal its own oral obesity drug. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
Dec 23, 2025
Why Abivax Stock Was on Fire Today
Investors were excited about the possibility of a buyout with a high price tag.
Dec 23, 2025
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Dec 23, 2025
The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso
Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.
Dec 23, 2025
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
Dec 23, 2025
Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy
Novo Nordisk shares climbed after U.S. regulators approved a tablet version of Ozempic and Wegovy, paving the way for the Danish drugmaker to start selling the first GLP-1 weight-loss pill. The Food and Drug Administration’s green light is expected to broaden the use of the class of drugs to which Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound and Mounjaro belong, ushering in a new era of the obesity-drug revolution. Shares in Novo Nordisk rose as much as 8% in European morning trading Tuesday.
Dec 23, 2025
Pill Version of Wegovy Is Approved for Use in the U.S.
Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.
Dec 23, 2025
Wegovy Pill Approval Sends Novo Nordisk Stock Soaring. What It Means for Eli Lilly.
Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss pill in the U.S. Novo’s American depositary receipts were up 7.3% at $51.61 after the company announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound. Novo said it expects to launch the Wegovy pill in the U.S. in early January.
Dec 23, 2025
These Stocks Moved the Most Today: Novo Nordisk, ServiceNow, Micron, DJT, Freeport-McMoRan, Zim, and More
Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.
Dec 23, 2025
Health Care Roundup: Market Talk
0549 ET – Novo Nordisk should benefit from U.S. approval of a pill version of Wegovy, AJ Bell’s Russ Mould writes in a note. U.S. regulators approved the first GLP-1 weight-loss pill, a tablet formulation of Novo Nordisk’s Ozempic and Wegovy. The decision gives the Danish drugmaker an early advantage in the race to bring an oral obesity treatment to market, he says.
Dec 23, 2025
Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug
The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped.
Dec 23, 2025
Arrival of GLP-1 weight-loss pill creates new headache for food, drink makers
Novo Nordisk’s FDA-approved Wegovy pill set to land on US shelves in January.
Dec 23, 2025
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.
Dec 23, 2025
Trending tickers: Tesla, Novo Nordisk, Starfighters Space, and Pets at Home
The latest investor updates on stocks that are trending on Tuesday
Dec 23, 2025
Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?
Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient — semaglutide — as the injectable Wegovy and Ozempic, but in a higher 25 mg dose to achieve comparable efficacy despite lower absorption because it is taken orally. ... Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?
Dec 23, 2025
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill
On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.
Dec 23, 2025
Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market
Weight-Loss Drugs Face a 2026 Inflection Point. Here's What Changes Next
Dec 22, 2025
BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026. On December 15, Bank of America analyst Jason Gerberry lowered the firm’s price target on Eli Lilly to $1,268 from $1,286 with a Buy rating on the shares. BofA remains bullish on Eli Lilly’s stock due to the company’s […]
Dec 22, 2025
Abivax soars on report of Eli Lilly meeting French officials over possible deal
Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company.
Dec 22, 2025
Top Analyst Reports for Eli Lilly, Shell & ICICI Bank
LLY's strong GLP-1 demand, international launches and new drug contributions highlight why it leads today's top analyst reports lineup.
Dec 22, 2025
Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends
XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.
Dec 22, 2025
Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment
Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 from $951 while reiterating a Buy rating on the stock. On December 12, Eli Lilly and Company provided updated data […]
Dec 22, 2025
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Dec 22, 2025
Sector Update: Health Care Stocks Higher in Afternoon Trading
Health care stocks advanced Monday afternoon, with the NYSE Health Care Index up 0.5% and the State
Dec 22, 2025
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks advanced late Monday afternoon with the NYSE Health Care Index rising 0.6% and th
Dec 22, 2025
Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY)
We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock. Over the course of the year, the CNBC TV host has praised the firm’s lead in the weight loss drug industry […]
Dec 22, 2025
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Renewed Tech Confidence
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad
Dec 22, 2025
FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers
FlyteHealth, a national leader in integrated cardio-kidney-metabolic care, today announced it will provide self-insured organizations with a new access pathway for obesity management medication from Eli Lilly and Company (Lilly) — supported by FlyteHealth's clinically rigorous, outcomes-driven care platform.
Dec 22, 2025
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.
Dec 22, 2025
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmun
Dec 22, 2025
Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)
Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and Company (NYSE:LLY) released updated results from Phase 3 EMBER-3 study of Inluriyo (imlunestrant), which is an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor […]
Dec 21, 2025
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss
The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications. Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance. Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the ATTAI
Dec 20, 2025
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly the problem Eli Lilly (LLY) seems to have cracked with its weight-loss pill. In a late-stage trial, patients switching from weekly injections to Lilly’s oral drug were able to maintain ...
Dec 20, 2025
Is It Too Late to Consider Eli Lilly After Its 568% Five Year Surge?
If you are wondering whether Eli Lilly is still worth buying after its huge run, you are not alone, and this article is going to unpack what the current price is really implying. The stock just closed at $1,056.88, adding 2.9% over the last week and 35.8% year to date, while compounding an eye catching 568.2% over five years. Investors have been digesting a steady flow of developments around Eli Lilly's obesity and diabetes drug portfolio, alongside growing expectations for its pipeline in...
Dec 19, 2025
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
Dec 19, 2025
Pharma's $370B Bet on America: The ETF Plays for 2026
Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
Dec 19, 2025
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
Dec 19, 2025
Vanguard Health Care Fund's Strategic Moves: Spotlight on AbbVie Inc
Exploring the Fund's Recent Portfolio Adjustments
Dec 19, 2025
Elanco CEO Bites Off More Shares of Fast-Rising Stock
Elanco Animal Health stock is having a great year—and Chief Executive Jeffrey Simmons is champing at the bit. Simmons spent $478,500 to buy 22,000 shares of the stock on Dec. 11 for an average price of $21.75, according to a Form 4 filed with the Securities and Exchange Commission. The purchase was made by a revocable trust and brings his total indirect ownership to 167,000 shares.
Dec 19, 2025
Dow Jones Futures: Tech Stocks Eye Key Level; Oracle, Nike, FedEx In Focus
Futures signal the stock market may test key resistance again after Thursday's Micron-inflation gains. Oracle, FedEx, Nike are early movers.
Dec 19, 2025
Did Eli Lilly Just Find the Holy Grail of Weight Loss?
Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue growth in the midst of intense demand for obesity therapies. In a head-to-head Phase 3 trial, Zepbound demonstrated superior efficacy, with patients achieving 20.2% average weight ... Did Eli Lilly Just Find the Holy Grail of Weight Loss?
Dec 19, 2025
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
Dec 19, 2025
Dow Jones Futures: Stocks Rise On Micron, Inflation, But Don't Do This; Nike, Fed Earnings Late
Dow Jones futures were little changed overnight, along with S&P 500 futures and Nasdaq futures. FedEx and Nike reported after the close. The stock market rallied Thursday on a surprisingly tame CPI inflation report and strong Micron Technology earnings and blowout guidance.
Dec 19, 2025
Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock Looks Cheap.
The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and consume food.
Dec 19, 2025
White House Cuts Drug-Pricing Deals With Pharma Companies, Tilting System Toward Self-Pay
The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.
Dec 19, 2025
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Dec 19, 2025
Lilly says obesity pill can replace shot after weight loss
Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper
Dec 18, 2025
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the efficacy of its daily oral pill, orforglipron.
Dec 18, 2025
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Dec 18, 2025
Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role
NEW YORK, December 18, 2025--The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1 prescribing programs are transforming treatment access pathways. Yet findings from 953 surveyed GLP-1 prescribers reveal sharp divisions over how involved pharma should be in clinical evaluation and prescribing.
Dec 18, 2025
Eli Lilly (LLY) Gains Support From Daiwa and Goldman Sachs in Back-to-Back Calls
Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 price target on the stock. That move followed a similar call from Goldman Sachs earlier. On December […]
Dec 18, 2025
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.45% change from its previous close.
Dec 18, 2025
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
Dec 18, 2025
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Stree
Dec 18, 2025
3 Momentum Stocks That Could Continue Their Strong Run in 2026
AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.
Dec 18, 2025
Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound
FDA filing advances orforglipron as a needle-free GLP-1 alternative.
Dec 18, 2025
Market Chatter: Eli Lilly and Company to Reduce Prices of its Diabetes, Weight-Loss Drugs in Canada by 20% or More
Eli Lilly and Company (LLY) will reduce the prices of its diabetes and weight-loss drugs Mounjaro an
Dec 18, 2025
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $36.15 as of December 15th. Viking Therapeutics is a clinical-stage biotechnology company focused on metabolic and endocrine disorders, with its […]
Dec 18, 2025
Better Buy in 2026: Pfizer or Eli Lilly?
These two stocks have been going in opposite directions over the past few years.
Dec 18, 2025
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to rece
Dec 18, 2025
Eli Lilly Scores Another Major Win: Time to Buy?
The company is running circles around its competition.
Dec 18, 2025
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk
These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.
Dec 18, 2025
Better Buy in 2026: UnitedHealth Group or Eli Lilly?
These industry titans have gone in opposite directions this year; is that likely to change?
Dec 18, 2025
Eli Lilly, IBD Stock Of The Day, Proves The Merit Of Its Weight-Loss Pill
Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.
Dec 18, 2025
Lose Weight on Zepbound, Keep It Off With Eli Lilly’s New Pill? Data Say That Works.
Patients on the highly effective obesity treatments from Novo Nordisk and Eli Lilly face a dilemma after they lose weight on the drugs: Do you stay on the shots forever, or stop and risk gaining the weight back? Now, it looks like Eli Lilly has a solution. One idea, long discussed by Wall Street analysts, has been that Lilly and its peers could lock in long-term users with a pill for patients to switch to after shedding pounds on a shot like Lilly’s Zepbound or Novo Nordisk’s Wegovy.
Dec 18, 2025
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
Dec 17, 2025
Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica
The market is surging due to the rising prevalence of chronic diseases and a massive shift toward home-based self-administration. The rapid expansion of biologics necessitates advanced injectables, while smart, connected devices are enhancing patient adherence, fueling robust market growth globally.Chicago, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The global drug delivery devices market size was valued at US$ 212.6 billion in 2025 and is projected to reach US$ 450.7 billion by 2035, growing at a CAGR o
Dec 17, 2025
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio
NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of David Arthur as Chief Executive Officer.
Dec 17, 2025
Big Pharma stocks 'way undervalued,' says market expert
<body><p>STORY: Coons noted that although regulatory changes have "weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly."</p><p>The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.</p><p>Lilly also produces Kisunla, a drug to slow Alzheimer's.</p><p>"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market," said Coons, who added, "we do like Merck as well."</p></body>
Dec 17, 2025
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.
Dec 17, 2025
Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Dec 17, 2025
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.
Dec 17, 2025
Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly
Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at Duquesne Capital without a single losing year, but he does not own Nvidia (NASDAQ:NVDA), Palantir (NASDAQ:PLTR), and Eli Lilly (NYSE:LLY) today. We’ll look into why in a bit. Druckenmiller is a timeless icon who has ... Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly
Dec 17, 2025
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors
Dec 16, 2025
Is Eli Lilly a Buy Before 2026?
Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.
Dec 16, 2025
Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing
BOSTON, December 16, 2025--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs.
Dec 16, 2025
Lilly to participate in J.P. Morgan Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time.
Dec 16, 2025
Eli Lilly or Merck: Where Should Investors Put Their Money?
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
Dec 16, 2025
Where Will Eli Lilly Be in 10 Years?
In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.
Dec 16, 2025
Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative?
In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability...
Dec 16, 2025
Scotiabank Remains Bullish on Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. In another development, Eli Lilly and Company (NYSE:LLY) announced on […]
Dec 16, 2025
China's new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?
Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as "historic" and "the beginning of the end" for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural editi
Dec 16, 2025
Pfizer Adds to Its Big Bet on Weight Loss Drugs
A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.
Dec 16, 2025
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most
Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.
Dec 16, 2025
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More
Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week of 2025. Stocks rallied Monday on the open as traders tried to inject some holiday spirit, but by 12 noon ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More
Dec 16, 2025
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the stock benefited as investors rotated capital out of the volatile technology sector and into defensive names.
Dec 15, 2025
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dec 15, 2025
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Dec 15, 2025
Update: Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026
(Updates with Novo Nordisk's response in the fifth paragraph.) Eli Lilly's (LLY) experimental we
Dec 15, 2025
Sector Update: Health Care Stocks Gain Late Afternoon
Health care stocks rose late Monday afternoon with the NYSE Health Care Index gaining 1.2% and the S
Dec 15, 2025
Sector Update: Health Care Stocks Rise in Afternoon Trading
Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the State Stre
Dec 15, 2025
2 Predictions for Eli Lilly in 2026
Can anything stop this high-flying drugmaker?
Dec 15, 2025
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide ...
Dec 15, 2025
Eli Lilly Just Delivered Fantastic News to Investors
Eli Lilly shares have climbed in the double digits this year.
Dec 15, 2025
Dow Jones Futures Rise; Will AI Rebound Or Drag Down Market? Tesla, Eli Lilly In Buy Areas
Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs last week. Tesla and Eli Lilly are in buy zones.
Dec 15, 2025
Eli Lilly (LLY): Assessing Valuation After Another Strong Share Price Run
Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the past week and more than 30% this year, as investors lean into its diabetes and obesity franchise. See our latest analysis for Eli Lilly. With the share price now around $1,027.51 and a powerful 90 day share price return of about 36%, momentum looks firmly intact and echoes Eli Lilly’s multi year total shareholder return that has hugely rewarded patient holders. If Eli...
Dec 13, 2025
My Top 3 Healthcare Stocks to Buy in 2026
These habitual market beaters can pull it off again.
Dec 13, 2025
Eli Lilly Leads Five Stocks Near Buy Points In Divided Market
Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks struggle.
Dec 13, 2025
Dow Jones Futures: Market Rally Divided, What To Do Now; Tesla, Eli Lilly In Buy Areas
Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs last week. Tesla and Eli Lilly are in buy zones.
Dec 13, 2025
Stock Market Week Ahead: A Catch-Up Week For Econ Data
Micron and Nike are among the week's big earnings reports. But economic news may steal the show, as the flow of federal attempts to recover.
Dec 13, 2025
AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock
AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
Dec 12, 2025
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
Dec 12, 2025
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.
Dec 12, 2025
Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026
Eli Lilly's (LLY) experimental weight-loss pill orforglipron may receive US Food and Drug Administra
Dec 12, 2025
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound
Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in 2025.
Dec 12, 2025
Sector Update: Health Care Stocks Edge Higher Friday Afternoon
Health care stocks edged up in Friday afternoon trading, with the NYSE Health Care Index adding 0.2%
Dec 12, 2025
Ozempic launches in India at $24 a week as Novo targets booming market
<body><p>STORY: Novo Nordisk launched Ozempic in India on Friday (December 12).</p><p>The Danish drugmaker priced the weight-loss drug at just over $24 per week for a 0.25 mg dose.</p><p>Novo is targeting a booming diabetes and obesity market in the country.</p><p>India has the world’s second-largest population of type 2 diabetes patients after China, and rising obesity rates.</p><p>That has turned it into a key battleground for weight-loss drugs</p><p>Ozempic has become a global bestseller and is widely used for weight loss.</p><p>Novo has said the drug also lowers the risk of cardiovascular events and kidney issues.</p><p>Friday's update is a bright spot in a challenging year for Novo.</p><p>It has faced strong competition from U.S. rival Eli Lilly and seen its share price drop heavily.</p></body>
Dec 12, 2025
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.2% and the S
Dec 12, 2025
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
Dec 12, 2025
Novo Nordisk Stumbles as Obesity Drug Race Heats Up
Europe's former pharma king is in freefall as Eli Lilly tightens its grip and investors demand answers.
Dec 12, 2025
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026.
Dec 12, 2025
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (MBC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. As monotherapy, imlunestrant demonstrated a clinically meaningful 38% reduction in the
Dec 12, 2025
Think Eli Lilly Is Expensive? This Metric Says Otherwise.
The pharmaceutical stock can still deliver.
Dec 12, 2025
Why a Budding Drug-Price Revolution Isn’t Quite What It Seems
Companies like Cigna and CVS are promising simpler prices, but the behind-the-scenes system remains complex.
Dec 12, 2025
Rival Healthcare Proposals Fail in Senate
A Democratic proposal to extend enhanced ACA subsidies failed in the Senate. It’s just weeks to go until millions of Americans covered under the Affordable Care Act face soaring costs for their coverage when the subsidies lapse. The shift is a huge departure from how pharma companies have sold drugs for decades and threatens the multibillion-dollar business of firms that have traditionally filled prescriptions.
Dec 12, 2025
Dow Jones Futures: Stock Market Strong Outside AI; Tesla, Eli Lilly In Buy Areas
Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs last week. Tesla and Eli Lilly are in buy zones.
Dec 12, 2025
Dow Jones, Russell 2000 Hit Highs, Buoyed By Fed; Oracle, Broadcom Weigh On Techs: Weekly Review
The Dow Jones and Russell 2000 hit record highs this past week, buoyed by a Fed rate cut and dovish Fed Chief Powell. Broadcom and Oracle weighed on techs.
Dec 12, 2025
Dow Jones Futures Rise, Techs Fall; Broadcom Latest AI Giant To Tumble On Earnings
The Dow Jones and Russell 2000 hit record highs while the Nasdaq slashed early losses. Broadcom sees AI chip sales doubling.
Dec 12, 2025
Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10
On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young as 10.
Dec 12, 2025
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.
Dec 12, 2025
Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?
Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...
Dec 11, 2025
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
Dec 11, 2025
Eli Lilly (LLY) Stock Is Up, What You Need To Know
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide.
Dec 11, 2025
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
Dec 11, 2025
Eli Lilly Says Trial of Weight-Loss Drug Retatrutide Yields Encouraging Results
Eli Lilly (LLY) said Thursday that a late-stage trial of retatrutide, its injectable weight-loss dru
Dec 11, 2025
How major US stock indexes fared Thursday, 12/11/2025
The Dow Jones Industrial Average jumped 646 points and topped its own record set last month. Weakness for AI-related stocks, though, weighed on the Nasdaq composite, which fell 0.3%. Gains for Eli Lilly, banks and smaller stocks helped offset a steep drop for Oracle, whose plans for increased spending on AI surprised analysts.
Dec 11, 2025
Eli Lilly Stock Rises After New Obesity Drug Crushes Phase 3 Goals
Lilly Boosts Lead in Weight-Loss Race as New Drug Hits All Endpoints
Dec 11, 2025
Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes
Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move […]
Dec 11, 2025
Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide
This article first appeared on GuruFocus. Eli Lilly (LLY, Financials) reported late-stage results showing its next-generation obesity drug retatrutide produced the strongest weight loss seen so far in a phase-three trial and reduced knee pain in patients with obesity and osteoarthritis. The highest dose led to 23.7% average weight loss at 68 weeks when including all participants and 28.7% among those who completed treatment.
Dec 11, 2025
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
Dec 11, 2025
Sector Update: Health Care Stocks Rise Thursday Afternoon
Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea
Dec 11, 2025
Eli Lilly's obesity drug trial results, Coca-Cola names next CEO
Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including the results of Eli Lilly's (LLY) latest obesity drug test, Coca-Cola (KO) named Henrique Braun as the next CEO after current chief executive James Quincey steps down from the role at the end of March 2026, and Gemini Space Station (GEMI) receiving approval to operate as a predictions market by the Commodity Futures Trading Commission (CFTC). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
Dec 11, 2025
Missed Ozempic? Lilly's Next Drug Could Be Even Bigger
Retatrutide just delivered over 23% weight loss in trials, raising the stakes in the $100B obesity race.
Dec 11, 2025
New Lilly Shot Reduces Body Weight by 23% in Study
A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.
Dec 11, 2025
Top Midday Stories: Oracle Shares Tumble After Revenue Miss; Lilly's Next-Gen Weight-Loss Drug Hits Primary Endpoints
The Dow Jones Industrial Average was down, while the S&P 500 and Nasdaq Composite were also lower in
Dec 11, 2025
Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened
The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021. “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,” said Paul Major, a portfolio manager at Bellevue Asset Management. Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company’s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review.
Dec 11, 2025
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta
Dec 11, 2025
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
Dec 11, 2025
Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial
Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.
Dec 11, 2025
Stocks to Watch Thursday: Disney, Eli Lilly, Coca-Cola, Rivian
↗️ Disney (DIS): The company is investing $1 billion in OpenAI and will license its characters for use in ChatGPT and videos. Shares gained 2.4%. The deal was unveiled after Disney accused Google of infringing its copyrights "on a massive scale,” highlighting its carrot-and-stick approach to AI.
Dec 11, 2025
Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss
Eli Lilly is putting the "obesity field on notice again," an analyst said Thursday after its next-gen delivered 28.7% weight loss.
Dec 11, 2025
Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro’s Definition of ‘Quality’
Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.
Dec 11, 2025
Eli Lilly’s Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.
The company said some patients had dropped out of the trial because they felt they were losing too much weight.
Dec 11, 2025
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
Dec 10, 2025
Eli Lilly to Invest $6 Billion in New Alabama Manufacturing Plant
Project expands U.S. production capacity as demand for weight-loss drugs grows
Dec 10, 2025
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
Dec 10, 2025
Eli Lilly Plans $6B Investment in New Alabama Manufacturing Site
Project aims to boost supply of next-generation obesity drugs as demand keeps climbing.
Dec 10, 2025
Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica
Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either […]
Dec 10, 2025
China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer
US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050
Dec 10, 2025
Hims stock falls after lawmakers propose GLP-1 compounding restrictions
Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.
Dec 10, 2025
Warning: This Skyrocketing Stock Has a Hidden Risk
Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.
Dec 10, 2025
Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility
The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.
Dec 10, 2025
Eli Lilly's Weight-Loss Drugs Drove Its Stock Higher This Year. A New Plant in Alabama Could Boost Production
Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss pill.
Dec 10, 2025
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
Dec 9, 2025
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
Dec 9, 2025
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Dec 9, 2025
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.
Dec 9, 2025
Cramer Loves These Dividend Stocks
Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable insights. Known for his high-energy delivery and colorful metaphors, Cramer blends deep market knowledge with an ability to distill complex financial trends into digestible advice. While he doesn’t exclusively focus on dividend stocks, his analysis often ... Cramer Loves These Dividend Stocks
Dec 9, 2025
Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill
Agreement deepens company's push into fast-growing weight-loss market
Dec 9, 2025
Wall Street Remains Cautious on Molson Coors Beverage Company (TAP)
Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered its price target for the stock to $50 from $52, while keeping a Neutral rating. The firm said it was revising its price target, taking into account recent developments in […]
Dec 9, 2025
How Lilly uses Big Pharma heft to lift up-and-coming biotechs
With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.
Dec 9, 2025
Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer
MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).
Dec 9, 2025
1 Major Factor Behind the Healthcare Sector's Recent Surge
Blockbuster drugs are a major driver of the growth of healthcare stocks.
Dec 9, 2025
2 Potential Stock Splits to Watch for in 2026
After experiencing incredible rallies during 2025, these two stocks could decide to "split it" in 2026.
Dec 9, 2025
Pfizer dips into China for another try at an obesity pill
A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.
Dec 9, 2025
Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness.EXTON, PA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted National Priority Vouchers, and thus expedited review, to Eli Lilly’s orforglipron and a high-dose formulation
Dec 9, 2025
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right
Dec 9, 2025
Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.
Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.
Dec 9, 2025
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37];
Dec 9, 2025
Review Preview: Fed Jitters
The Fed is expected to cut rates another quarter point on Wednesday. The question is what comes next.
Dec 9, 2025
In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?
In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.
Dec 9, 2025
Eli Lilly to Build $6 Billion Alabama Plant as Part of U.S. Investment
The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.
Dec 9, 2025
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dec 8, 2025
Jim Cramer Prefers Buying Eli Lilly When People Are “Getting Antsy”
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed, along with the tech battleground. A caller asked Cramer about an optimal entry point into the stock, and he replied: “I think that people now are getting antsy and thinking that it’s really breaking down. That’s probably when I want to start […]
Dec 8, 2025
Top-Ranked ETFs to Power Your Portfolio Higher
With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.
Dec 8, 2025
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
Dec 8, 2025
Lilly declares first-quarter 2026 dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.
Dec 8, 2025
Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”
Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and […]
Dec 8, 2025
Carolyn Bertozzi returns to Lilly board of directors
The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.
Dec 8, 2025
Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035
Neuroblastoma, a rare cancer mainly affecting children, is witnessing advancements in treatments, notably through immunotherapy, which has improved survival rates. Key innovations like gene and CAR-T cell therapies are accelerated by substantial government and private investments, transforming market dynamics. However, high treatment costs pose a challenge, particularly in low-resource settings. Leaders like Novartis and Eli Lilly drive innovation, focusing on sustainable products. The market's
Dec 8, 2025
Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill
Shares of Structure Therapeutics surged Monday after the biotechnology company said an experimental pill helped people lose substantial weight in a mid-stage clinical trial. The trial results raised hopes for high sales in the booming obesity-drug market. Analysts said the efficacy could make Structure’s pill competitive with Eli Lilly’s orforglipron, which Lilly hopes to introduce next year.
Dec 8, 2025
Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.
Dec 8, 2025
Structure Therapeutics Soars; CEO Says It Could Have 'Best In Class' Weight-Loss Drug
Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.
Dec 8, 2025
Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk
Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.
Dec 8, 2025
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump
Dec 8, 2025
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve or were BTK inhibitor-naïve. Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compar
Dec 7, 2025
At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma
In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.
Dec 7, 2025
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]
Dec 6, 2025
Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?
This is no reason to panic.
Dec 6, 2025
Is It Too Late To Consider Eli Lilly After Its Massive Five Year Share Price Surge?
If you are wondering whether Eli Lilly is still worth buying after its massive run or if the best days are already priced in, you are not alone, and that is exactly what we are going to unpack here. The stock has pulled back around 8.1% over the last week, but it is still up 11.9% over the past month, 30.4% year to date, and 564.0% over five years, which says a lot about how the market views its long term growth story. Recently, the spotlight has stayed firmly on Eli Lilly thanks to ongoing...
Dec 5, 2025
With Netflix's 10-for-1 Stock Split Complete, Here Are 3 Growth Stocks to Buy in December That Could Issue Stock Splits in 2026
Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new year.
Dec 5, 2025
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
Dec 5, 2025
Do These 3 Healthcare Stocks Need a Checkup?
These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?
Dec 5, 2025
Meet the Supercharged Growth Stock That Could Join Apple, Nvidia, Microsoft, and Alphabet in the $2 Trillion Club by 2028
Eli Lilly's stock price and market cap are poised to explode with the GLP-1 market.
Dec 5, 2025
Dow Jones Futures Rise; Netflix To Buy Warner Bros
Futures rose with the market nearing record highs. Netflix agreed to buy Warner Bros. Will regulators agree? Ulta Beauty led earnings late.
Dec 5, 2025
Eli Lilly, Alphabet Among Megacap Leaders On This Growth List
Eli Lilly, Alphabet are among leading stocks in the IBD 50 list of growth stocks. Taiwan Semiconductor and AppLovin are near buy points.
Dec 5, 2025
Dow Jones Futures Rise After Small Caps Surge, Eli Lilly Tested; 5 Stocks In Buy Zones
Small caps nearly hit all-time highs as the major indexes paused. Eli Lilly is at a key level while Robinhood led new buys. Ulta Beauty led earnings late.
Dec 5, 2025
Nvidia, Palantir AWOL, But Top Funds Go Bonkers For This AI Mobilizer
New buys by the best mutual funds show AI stocks still in demand as AppLovin, Google and Broadcom shine. But Nvidia, Palantir go AWOL.
Dec 5, 2025
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.
Dec 4, 2025
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Dec 4, 2025
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,075.47 as of November 28th. LLY’s trailing and forward P/E were 52.69 and 33.90, respectively according to Yahoo Finance. Eli Lilly […]
Dec 4, 2025
Avidity Biosciences, Inc. (RNA): A Bull Case Theory
We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.’s share was trading at $71.54 as of December 2nd. Novartis is acquiring Avidity RNA, a pre-Phase 3 biotech company, in a straightforward deal with no overlap between the two businesses. The […]
Dec 4, 2025
Denmark's $600 Billion Economy Just Got a Boost--Thanks to One Drugmaker
Novo Nordisk's weight on GDP, jobs, and exports is reshaping Denmark's growth story despite layoffs and tariff headwinds.
Dec 4, 2025
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
Dec 4, 2025
Danaher Stock Earns Relative Strength Rating Upgrade
Danaher stock had its Relative Strength (RS) Rating upgraded from 68 to 72 Thursday — a welcome improvement, but still shy of the 80 or higher score you prefer to see. When To Sell Stocks To Lock In Profits And Minimize Losses IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score.
Dec 4, 2025
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
Dec 3, 2025
Tech Is Getting Left Behind in the S&P 500’s Latest Rebound
Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record. In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp. The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.
Dec 3, 2025
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts
Dec 3, 2025
Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains
Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company (NYSE:LLY) reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse. The company’s stock has rallied more […]
Dec 3, 2025
Excelsior Sciences Raises $95 Million to Transform Small Molecule Discovery and Manufacturing with Novel Chemistry that Machines Can Do
NEW YORK, December 03, 2025--Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules.
Dec 3, 2025
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year
A key catalyst may be right around the corner.
Dec 3, 2025
2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years
They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.
Dec 3, 2025
Walmart Stock Rallies, Pushing Market Cap Above $900 Billion
Walmart's market value closed above a $900 billion for the first time on Wednesday. The retailer’s stock rose 1.8%, making it the 12th U.S. company to surpass the milestone, according to Dow Jones Market Data.
Dec 3, 2025
As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?
Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.
Dec 3, 2025
Best-Performing ETFs of November
November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.
Dec 2, 2025
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
Dec 2, 2025
Morgan Stanley Bullish on Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]
Dec 2, 2025
ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman
By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth and leadership in rare and inflammatory diseases,” said Kenji Cunnion, M.D., MPH, ReAlta’s co-founder, Chief […]
Dec 2, 2025
Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034
Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.c
Dec 2, 2025
Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair
Janux’s “masked” T cell engager had a lower response rate than reported last year. Elsewhere, Lilly dropped Zepbound’s price and ACIP named a new chairman days before a key vaccine meeting.
Dec 2, 2025
Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple
After a rough pullback, the major indices are attempting to rebound higher. Helping, not only is Bitcoin starting to rebound, but so are down but not out tech stocks. Plus, markets are optimistic that the Federal Reserve will cut interest rates again next week. We also continue to see a significant number of upgrades from ... Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple
Dec 2, 2025
The weight loss drug boom is just getting started: What's next
New pill versions of weight loss drugs, lower prices, and patent expirations will all drive GLP-1 demand in 2026
Dec 1, 2025
US Stock Market Today: S&P 500 Futures Dip as Rate Cut Uncertainty Weighs
The Morning Bull - US Market Morning Update Monday, Dec, 1 2025 US stock futures are drifting lower this morning as investors digest two big drivers: rising expectations of a Federal Reserve interest rate cut and a fresh jump in Treasury yields. The yield on the 10-year US government bond climbed to 4.04%, which signals that borrowing money is still expensive for both consumers and businesses. At the same time, market chatter points to a likely rate cut as soon as next week, which could make...
Dec 1, 2025
AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
Dec 1, 2025
Eli Lilly cuts cash price for Zepbound weight loss drug vials
The announcement came just weeks after rival Novo Nordisk cut prices for cash buyers of its top-selling weight loss drugs Ozempic and Wegovy
Dec 1, 2025
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
Dec 1, 2025
Eli Lilly Cuts Cash Prices for Zepbound Vials on LillyDirect
The company lowered monthly out-of-pocket costs as access initiatives expand.
Dec 1, 2025
Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound
Eli Lilly is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, that would be a saving of about $50. It's part of the price war with rival Novo Nordisk. Bloomberg's Madison Muller reports.
Dec 1, 2025
How Analyst Views Are Shaping Eli Lilly’s Evolving Growth Story
Eli Lilly’s stock has recently seen its consensus analyst price target rise from $1,003 to $1,024. This change reflects growing optimism among investors and follows fresh analyst reports and updated financial models, which are influenced by new product launches and expanding drug coverage. Stay tuned to discover how you can track these evolving perspectives and remain informed about future changes in Eli Lilly’s investment narrative. Stay updated as the Fair Value for Eli Lilly shifts by...
Dec 1, 2025
Are GLP-1s The New Performance-Enhancing Drug For Careers?
Some professions — think tenured professor or Supreme Court justice — are largely insulated from the pressure to maintain a specific look. The same cannot be said in the high-stakes arenas of finance, real estate and design, where the quest for a competitive edge has well-established self-maintenance rituals: coloring gray hairs, meticulously curated wardrobe and submitting oneself to Botox needles. Now, that pursuit has evolved to include another new, potent class of injectable: glucagon-like p
Dec 1, 2025
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a LiquidationREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by E
Dec 1, 2025
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?
Dec 1, 2025
Stocks To Watch As Google Drives Rattled But Rebounding Market
As the Nasdaq holds tough after a five-day win streak, Google stock, Robinhood and others land on list of stocks to watch.
Dec 1, 2025
U.S., U.K. Strike Deal on Higher Drug Prices
The move marks a victory for the Trump administration’s campaign to get other countries to pay more for drugs.
Dec 1, 2025
DraftKings Stock Has Gotten Whacked. Why JPMorgan Says It Can Mount a Comeback.
Kalshi and Polymarket may not be a threat for much longer, as the gambling company gears up to launch its own prediction market.
Dec 1, 2025
Trillion-Dollar Companies Now Go To 11; Google Is No. 3
Eli Lilly recently became the 11th stock with a trillion-dollar valuation. S&P 500 titans Nvidia and Apple lead, but Google is rising fast.
Dec 1, 2025
Eli Lilly cuts price for popular weight loss drug Zepbound
Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's LillyDirect website.
Dec 1, 2025
Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal
Eli Lilly said Monday that it's reducing the price of its popular weight-loss drug Zepbound on its LillyDirect platform, about a month after striking a deal with the Trump administration to lower drug costs.
Dec 1, 2025
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing
The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.
Dec 1, 2025
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.
Nov 30, 2025
Why Novo Nordisk Stock Just Hit a 4-Year Low
Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.
Nov 30, 2025
Should You Invest in This Under-the-Radar Weight Loss Stock?
This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon?
Nov 30, 2025
Market Data
Out of nowhere, on a holiday week no less, it seemed the stock market got a bid. The result was weekly gains for all the major averages. The Standard & Poor's 500 ended about 1% below its 52-week high, and Eli Lilly ended the week still sporting a market capitalization of $1 trillion. In the ...
Nov 30, 2025
Eli Lilly (LLY) Valuation in Focus After Hitting $1 Trillion on Obesity Drug Breakthroughs
Eli Lilly (LLY) just crossed a $1 trillion market cap, capturing attention on Wall Street as diabetes and weight-loss drugs continue to propel the company’s value. Demand for its GLP-1 therapies, such as Zepbound and Mounjaro, has surged, due in part to strong clinical trial results and wider coverage from Medicare and Medicaid. See our latest analysis for Eli Lilly. Shares in Eli Lilly have soared over the past year, with momentum building thanks to breakthrough obesity and diabetes drug...
Nov 29, 2025
Is Eli Lilly a Millionaire Maker?
Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.
Nov 29, 2025
These Are 2 of the Smartest Growth Stocks to Invest $5,000 in Today
These top growth stocks are worth a second look.
Nov 29, 2025
MarketBeat Week in Review – 11/24 - 11/28
Stocks were modestly higher in a shortened trading week; next week will bring a better sense of institutional sentiment heading into the holiday season
Nov 29, 2025
Why Eli Lilly's 'market-cap explosion' might be 'misplaced'
Mizuho Americas healthcare equity strategist, Jared Holz, joins Market Catalysts host Julie Hyman to discuss Eli Lilly's (LLY) stock action, how the GLP-1 market has played a part, and whether Eli Lilly will see serious competition in the oral GLP-1 market moving forward. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
Nov 28, 2025
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Nov 28, 2025
Zacks Investment Ideas feature highlights Lilly
Lilly have been highlighted in this Investment Ideas article.
Nov 28, 2025
A Conductor For The Orchestra: Seasoned Healthcare Executive Raises $52 Million For An AI Health Startup
Michelle Carnahan has spent the better part of the last three decades working in healthcare at companies like Thirty Madison and Eli Lilly (NYSE:LLY). Now, the entrepreneur has raised $52 million in seed money for her own startup, Arbiter, a platform that connects health care professionals and payers to provide better patient care. The money has all been raised from family offices, including TriEdge Investments, MFO Ventures, and WindRose Health Investors, according to the company's funding anno
Nov 28, 2025
These Were the S&P 500’s Best and Worst Stocks in November
Lithium miner Albemarle came out on top, while Super Micro Computer led the list of worst performers.
Nov 28, 2025
Top Stock Movers Now: Intel Rises, Nvidia and Oracle Slip; Bitcoin Price Near $92,000
Shares of U.S. chipmaker Intel were leading the S&P higher as stocks edged upward on a holiday-shortened Black Friday session expected to be light on trading volume and corporate news.
Nov 28, 2025
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
The possibility of adding a new Big Tech customer helped lift an American chipmaker's stock on Friday, Nov. 28, 2025, while a recently hot pharmaceutical stock cooled.
Nov 28, 2025
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
Nov 27, 2025
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Nov 27, 2025
Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031
It's not only tech companies that can get to that market valuation.
Nov 27, 2025
Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!
As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.
Nov 27, 2025
Why Eli Lilly (LLY) Hit $1 Trillion as Obesity Drug Momentum Ignites Investor Optimism
Eli Lilly recently became the first healthcare company to surpass a $1 trillion market capitalization, propelled by surging demand for its GLP-1-based diabetes and obesity drugs, Zepbound and Mounjaro, alongside significant pipeline developments and expanded Medicare and Medicaid coverage. This milestone reflects growing investor optimism about Eli Lilly's innovation pipeline, its manufacturing investments, and the potential for its upcoming oral obesity treatment to further transform the...
Nov 26, 2025
BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood
Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.
Nov 26, 2025
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
Nov 26, 2025
JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating
Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term. On‍ November 18, JPMorgan analyst Chris Scho‍tt r‌aised the firm‍’s‍ price ta‌rget on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 wh‍ile maintaining an Overw‍eight ratin⁠g after meetings with management. JPMorgan said the di‌scu‌ss⁠ions‌ re‌inforced its positive […]
Nov 26, 2025
Hedge Funds Pile Into Health Stocks Leading Market in Rotation
The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.
Nov 26, 2025
Jim Cramer Discusses Eli Lilly (LLY) Touching the Trillion Dollar Market Value
We recently published 11 Stocks Jim Cramer Shared His Insights On. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the pharmaceutical space. He has remained optimistic about the firm throughout the year and praised its lead in the weight […]
Nov 26, 2025
Novo Nordisk Faces 71% Medicare Price Cuts on Ozempic and Wegovy
U.S. government move slashes costs for key diabetes and weight-loss drugs beginning in 2027.
Nov 26, 2025
Healthcare Equity ETF (GDOC) Hits Fresh 52-Week High
GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.
Nov 26, 2025
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
Nov 26, 2025
Stock Split Watch: Is Eli Lilly Next?
The stock recently reached beyond $1,000.
Nov 26, 2025
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
Nov 26, 2025
Did Pfizer Just Say "Checkmate" to Novo Nordisk?
The weight loss drug market may approach almost $100 billion by the end of the decade.
Nov 26, 2025
Trump administration slashes Medicare price for Ozempic and Wegovy
The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare...
Nov 26, 2025
J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?
J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.
Nov 25, 2025
Healthcare ETF (IYH) Hits New 52-Week High
IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.
Nov 25, 2025
Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why
We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, […]
Nov 25, 2025
4 takeaways from pharma’s manufacturing boom
As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.
Nov 25, 2025
Novo's Comeback Shot? Weight-Loss Drug Triggers Surprise Rally After Brutal Stock Crash
A promising next-gen diabetes treatment just gave Novo Nordisk its first real jolt of hope in months.
Nov 25, 2025
Citizens Financial Group And 2 Other Stocks That May Be Priced Below Their Estimated Worth
As the U.S. stock market kicks off a holiday-shortened trading week with significant gains, investors are buoyed by optimism around a potential Federal Reserve interest rate cut in December. In this environment of heightened confidence, identifying stocks that may be undervalued compared to their estimated worth can be particularly appealing, as they offer opportunities for growth amidst broader market enthusiasm.
Nov 25, 2025
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI
LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.
Nov 25, 2025
Here's Why Novo Nordisk Stock Popped Today
Good news from a GLP-1 receptor agonist clinical trial hit the market today.
Nov 25, 2025
Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial
The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.
Nov 25, 2025
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
Shares, though, were punished Monday after the drug maker said its blockbuster obesity treatment Wegovy failed to slow Alzheimer’s.
Nov 25, 2025
Top analyst drops jaw-dropping price target on Eli Lilly stock
Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100. For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price. ...
Nov 25, 2025
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?
Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.
Nov 25, 2025
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling
Eli Lilly became the first drugmaker to surpass a trillion-dollar valuation by driving revenue through mass market adoption rather than price increases.
Nov 25, 2025
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
Nov 24, 2025
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.
Nov 24, 2025
Moderna is the S&P 500's most shorted stock: Here's why
President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.
Nov 24, 2025
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
Nov 24, 2025
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9 in Orlando, Florida.
Nov 24, 2025
Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock
A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.
Nov 24, 2025
Sector Update: Health Care Stocks Advance in Afternoon Trading
Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car
Nov 24, 2025
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the H
Nov 24, 2025
Eli Lilly Benefits From 'Broadening' GLP-1 Market, Morgan Stanley Says
Eli Lilly (LLY) is benefiting from the "broadening" GLP-1 market for obesity and type-2 diabetes, Mo
Nov 24, 2025
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12 in San Antonio, Texas. These updates reflect Lilly's continued progress across key pathways in hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer, the most common form of breast cancer.1
Nov 24, 2025
Ukraine peace, robotaxis and pharma: what's moving stocks
The selloff in European defense stocks (BA.L, RHM.DE, HO.PA, BAB.L) deepens as hopes grow around a peace deal draft for Ukraine and Russia. China's robotaxi firm WeRide (WRD) rallies on a massive revenue jump - even though the firm is still burning cash. In pharma, after Eli Lilly (LLY) hit $1 trillion: Bayer (BAYN.DE) stock flies, Novo Nordisk (NVO, NOVO-B.CO) tanks. For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.
Nov 24, 2025
Billionaire Stanley Druckenmiller Dropped Nvidia, Palantir, and Eli Lilly Over the Past Year and Just Bought the 2 Cheapest Magnificent Seven Stocks.
These Magnificent Seven players are well-positioned to benefit in the AI boom.
Nov 24, 2025
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.
Nov 24, 2025
Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's
Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo Nordisk stock recently stood about 5.7% lower. The shares have tumbled by nearly three-quarters since hitting a peak at 1,028 Danish kroner in June last year.
Nov 24, 2025
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials
A pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials.
Nov 24, 2025
These Stocks Are Moving the Most Today: Tesla, Alphabet, Strategy, Eli Lilly, and More
Investors are hopeful that the economic data due out this week will strengthen the case for a Fed rate cut. These stocks are rising.
Nov 24, 2025
Dow Jones Futures, Bitcoin Rise; Nvidia, Apple, Eli Lilly In Focus
The stock market needs to show a lot of strength after damaging recent losses. Watch Nvidia, Apple and Eli Lilly.
Nov 24, 2025
Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps
Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.
Nov 24, 2025
Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.
The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.
Nov 24, 2025
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
Fuelled by weight loss drug sales, Eli Lilly achieves a feat no healthcare company has before.
Nov 24, 2025
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.
Nov 23, 2025
2 Top Dividend Stocks for Growth-Oriented Investors
Who says you have to choose between the two?
Nov 23, 2025
T. Rowe Price insists investors will find 2026 less stressful
Maybe you have a big 401(k) account or an Individual Retirement Account. You would be within your rights if you found this week's market volatility — coming just seven months after April's Trump Tariff mini-crash — just a bit unsettling. Is the world about to fall apart? No, say ...
Nov 23, 2025
Dow Jones Futures: Stocks Bounce, Nvidia, Apple, Eli Lilly In Focus; Bitcoin The Weak Link?
The stock market rebounded Friday on Fed rate cut hopes but suffered damaging weekly losses. Nvidia, Apple and Eli Lilly are in focus.
Nov 23, 2025
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.
Nov 22, 2025
Weight-loss drug boom propels Eli Lilly to $1 trillion
Eli Lilly became the first healthcare company to enter into the $1 trillion market-cap club on Friday
Nov 21, 2025
The $1 Trillion Drug Bet: How Eli Lilly Outsprinted Big Tech on Fat, Pills, and Wall Street Dreams
Lilly just leapfrogged pharma history--and it's not done. A $40B pill could push it toward $1.4T next.
Nov 21, 2025
Eli Lilly reaches $1 trillion market value for first time
Weight-loss and diabetes drugs drive historic milestone
Nov 21, 2025
Lilly Breaks $1 Trillion Mark In Historic Milestone
Investors reward LLY's GLP-1 strength while Novo struggles
Nov 21, 2025
Eli Lilly becomes first pharma group to join $1tn club
Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1tn market valuation, a sharp turnaround from this summer when...
Nov 21, 2025
Evaluating Eli Lilly Shares After 30% Surge Driven by Obesity Drug Pipeline News
Curious whether Eli Lilly’s stock is still a smart buy after its rapid rise? Let’s break down the numbers and see if the current price matches up with real value. Shares have vaulted higher lately, climbing 30.5% in just the last month and notching a stunning 40.2% gain over the past year. Investors are watching Eli Lilly closely after headline-making developments in its obesity and diabetes drug pipeline sent the stock to new highs. This reflects excitement over blockbuster potential and...
Nov 21, 2025
Sector Update: Health Care Stocks Gain Friday Afternoon
Health care stocks were higher Friday afternoon, with the NYSE Health Care Index rising 2.5% and the
Nov 21, 2025
BJ's beats on earnings, Ross lifts outlook, Eli Lilly hits $1T
Market Catalysts host Julie Hyman tracks several of Friday's top trending stock tickers, including Eli Lilly (LLY), BJ's Wholesale Club (BJ), and Ross Stores (ROST). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
Nov 21, 2025
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health
Nov 21, 2025
Top Midday Stories: Lilly Becomes First Pharma Company to Hit $1 Trillion Market Cap; Enviri to Sell Clean Earth to Veolia for $3.04 Billion
The major US stock indexes were up in late-morning trading Friday as investors remained concerned ov
Nov 21, 2025
Lilly first drugmaker to hit trillion-dollar club on weight-loss demand
<body><p>STORY: Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter an exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.</p><p>A more than 35% rally in the company's stock this year has largely been driven by the explosive growth of the weight-loss drug market.</p><p>Novo Nordisk had the early lead in the space, but Lilly's drugs - Mounjaro and Zepbound - have surged in popularity and helped eclipse its rival in prescriptions.</p><p>Friday's record high put Lilly's stock price at more than $1,060 a share, giving it one of the richest valuations in big pharma - about 50 times its anticipated earnings over the next 12 months, according to LSEG data.</p><p>Since the launch of Zepbound in late 2023, Lilly's stock has gained more than 75%, compared with an over 50% rise in the S&P 500 during the same period.</p><p>Wall Street estimates the overall weight-loss drug market to be worth $150 billion by 2030, with Lilly and Novo together controlling the majority of projected global sales.</p></body>
Nov 21, 2025
Analysts get more bullish on this non-tech stock
The market has been swinging recently, with the S&P 500 index down 1.5% and the Nasdaq Composite down more than 2% over the past month. Investors are now questioning whether the tech momentum can continue. Some non-tech stocks have performed well, and Eli Lilly (LLY) is one of them. Eli ...
Nov 21, 2025
The Score: Nvidia, Constellation, Eli Lilly, Gap and More Stocks That Defined the Week
Nvidia’s blockbuster results weren’t enough to quell growing fears of an AI bubble. Nvidia also increased its guidance for the current quarter. It was the stock market’s largest blown gain since April’s tariff-fueled market turmoil, and it extended a painful stretch for the stocks at the heart of the AI boom.
Nov 21, 2025
AI Stocks Are Taking a Beating. What to Buy Instead.
November has been NO-vember when it comes to tech stocks. Investors are shunning artificial-intelligence leaders and other momentum names. Investors seem to be embracing drug stocks, insurers, and medical equipment companies again.
Nov 21, 2025
Eli Lilly Becomes First Pharma To Join $1 Trillion Club Alongside Nvidia, Apple, Others
Eli Lilly on Friday became the first health care company to top $1 trillion in market capitalization, joining a club of mostly tech names.
Nov 21, 2025
These Stocks Moved the Most Today: Nvidia, Oracle, Alphabet, Strategy, Intuit, Lilly, Gap, Elastic, Veeva, and More
Stocks rallied Friday after the previous session’s selloff driven by concerns about bloated artificial-intelligence valuations. Nvidia’s report and better-than-expected guidance gave the market a solid read on artificial-intelligence demand but failed to reassure investors who have been fretting about where the money is coming from and whether it will be well spent. Local media reported this week that Taiwanese officials were investigating Wei-Jen Lo, who joined Intel in October.
Nov 21, 2025
Eli Lilly Stock Closes Above $1 Trillion After Climbing $400 Billion in 3 Months
It’s the only drug company ever to have a $1 trillion capitalization value; the other U.S. companies are tech giants and Berkshire Hathaway.
Nov 21, 2025
Eli Lilly becomes first healthcare company to hit $1 trillion
Zepbound and Mounjaro posted triple-digit revenue growth, making Lilly the first health industry giant to reach a trillion-dollar valuation.
Nov 21, 2025
Stocks to Watch Friday Recap: Eli Lilly, Intuit, Gap, Warner Bros.
↗️ Eli Lilly (LLY): The drugmaker became the first pharmaceutical company to hit a $1 trillion market capitalization. It ended the day with a market cap of $1.002 trillion after the stock rose 1.6%. Booming demand for its weight-loss drugs has boosted shares.
Nov 21, 2025
Lilly’s Sharp Rally Brings Market Cap to $1 Trillion
Eli Lilly (LLY) became the 10th U.S. company to reach the $1 trillion market cap milestone on Friday, following nine others that mostly come from technology. The Indianapolis-based drugmaker, the first pharmaceutical company to hit the 13-digit mark, rode a wave behind the booming market for weight-loss drugs.
Nov 21, 2025
Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here?
Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026.
Nov 21, 2025
Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs
Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and nearly 80% in the past two years. Analysts remain highly confident,...
Nov 21, 2025
A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
Stanley Druckenmiller just made major buys in three Mag 7 stocs; see why the he's doubling down on AI hyperscalers and what it means for your portfolio
Nov 21, 2025
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nov 20, 2025
How do Big Pharma employees rate their CEOs?
There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.
Nov 20, 2025
VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future
A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves
Nov 20, 2025
Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading
The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For
Nov 20, 2025
IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors
PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos Paya as Non-Executive Director. Carlos has a distinguished track record of leadership spanning academic medicine and the biopharmaceutical industry, with deep expertise in drug development and commercial strategy across early-stage start-ups to large-cap pharmaceutical companies.
Nov 20, 2025
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Nov 20, 2025
Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit
<body><p>STORY: Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's disease.</p><p>Two trials have been described by Novo as a "lottery ticket".</p><p>They're testing its older diabetes pill that has the same active ingredient as Ozempic and Wegovy in thousands of people with mild Alzheimer's.</p><p>The goal is to decrease patients' rate of cognitive decline by at least 20%.</p><p>Alzheimer's experts say success would usher in a convenient new treatment to slow progression in a condition that affects 50 million people globally.</p><p>Researchers expect to glean important clues for future study into how and why these types of drugs, which include Eli Lilly’s Zepbound and Mounjaro, may be useful against the disease.</p><p>There are currently two drugs approved for slowing Alzheimer's by removing amyloid from the brain.</p><p>They are Lilly's Kisunla, Leqembi from Eisai, and Biogen.</p><p>They were shown in clinical trials to slow disease progression by close to 30%.</p><p>Although they also carry the risk of serious side effects and require regular scans.</p><p>Novo is slated to present its results on December 3rd, although it could announce some data before then.</p></body>
Nov 20, 2025
Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly?
Novo Nordisk just addressed a problem that has prevented some from taking these drugs.
Nov 20, 2025
Novo Nordisk (NVO) To Lower US Prices of its Injectable Wegovy Obesity Drug
Novo Nordisk A/S (NYSE:NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo Nordisk A/S (NYSE:NVO) will lower the US prices of its injectable Wegovy obesity drug. The price reduction for injectable Wegovy follows the company’s earlier announcement on November 6, where it agreed with the US […]
Nov 19, 2025
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.
Nov 19, 2025
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
Nov 19, 2025
Eli Lilly Gains from Big Earnings, Bullish Inflows
Eli Lilly and Company (LLY) shares up 15,892% since Big Money bought big in 1990.
Nov 19, 2025
2 High-Flying Stocks with Exciting Potential and 1 We Find Risky
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
Nov 19, 2025
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
Eli Lilly and Company (NYSE: LLY) today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia, bringing its distinctive model of scientific partnership to a city known for shaping the future of medicine.
Nov 19, 2025
Head and Neck Squamous Cell Carcinoma Market Research Report 2025-2035: Sanofi, Sun Pharma, and Eli Lilly Lead Through the Development of New Drugs, Clinical Trials, Combination Treatment Strategies
The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for targeted therapies. Key innovations like immunotherapies, precision medicine, and early detection biomarkers are reshaping the market landscape, improving patient outcomes, and driving therapy adoption. Developed and emerging markets see enhanced care accessibility, propelled by investments in cancer i
Nov 19, 2025
Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies
Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati
Nov 19, 2025
The Zacks Analyst Blog Highlights Microsoft, Amazon.com and Eli Lilly
Microsoft posts strong cloud-fueled Q1 results as Azure surges and AI momentum builds, even as capacity limits pose near-term revenue constraints.
Nov 19, 2025
Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia
Breakthrough Properties today announced that it has partnered with Eli Lilly and Company (Lilly) to launch Lilly Gateway Labs at Breakthrough at 2300 Market Street in Philadelphia. This new partnership provides innovative biotech companies comprehensive access to move-in ready labs, fully-equipped workspaces, and amenities they need to succeed and grow.
Nov 19, 2025
EXPLORING THE GLOBAL TRANSFORMATION OF HEALTH CARE WITH ELI LILLY's CEO DAVE RICKS
T. Rowe Price, a global investment management firm and a leader in retirement, announced the latest episode of "The Angle," an investment-themed podcast focused on timely topics shaping financial markets and featuring executives from some of the world's leading companies.
Nov 19, 2025
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These stocks both have advanced in the double-digits in recent months.
Nov 19, 2025
Stock Split Watch: Could This Unstoppable Growth Stock Be Next?
Don't wait for a stock split to buy the stock, though.
Nov 19, 2025
Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win
Viking Therapeutics stock fell Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.
Nov 19, 2025
This Blue-Chip Stock Is a Heavy Weight in Weight-Loss Drugs
Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new all-time highs. Shares are up 43% over the past year. Analyst sentiment is overwhelmingly positive, with most major firms rating LLY...
Nov 19, 2025
Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.
FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.
Nov 19, 2025
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
Novo Nordisk's new pricing for its GLP-1 drugs is a strategic pivot to capture a mass market, pressure rivals, and secure long-term market dominance.
Nov 19, 2025
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.
Nov 19, 2025
TD Cowen Maintains Buy on Eli Lilly (LLY) After Government Deal
Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen reiterated its Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $960. This update came after the company announced an agreement with the US government to expand access […]
Nov 18, 2025
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
Nov 18, 2025
Jim Cramer Comments On Eli Lilly (LLY)’s Shares After Pfizer CEO’s Remarks
We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s attention. Throughout 2025, the CNBC TV host […]
Nov 18, 2025
Jim Cramer on Novo Nordisk: “You Gotta Let It Come Back a Little”
Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer expressed his thoughts on. A caller asked, as a long-time holder of substantial NVO shares that have significantly declined in value, if it is too late to exit the position. In response, Mad Money’s host said: “You gotta, okay, you gotta let it come […]
Nov 18, 2025
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
Nov 18, 2025
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.
Nov 18, 2025
Lilly to participate in Citi's 2025 Global Healthcare Conference
Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time.
Nov 18, 2025
Lilly's Donanemab Wins India Approval For Alzheimer's
Launch coming soon as India waits on final pricing plans
Nov 18, 2025
Top Research Reports for Microsoft, Amazon.com & Eli Lilly
Microsoft shines in Zacks' top picks as strong cloud and AI momentum drive standout quarterly results and reinforce long-term growth potential.
Nov 18, 2025
Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the rest of the branded pharmaceuticals stocks fared in Q3.
Nov 18, 2025
This Market Selloff Has Engulfed Stocks, Crypto, Gold. How the Fed Can Stop It.
Crypto caught in broad market selloff, food, restaurant companies feeling relief, U.S.-China trade deal is fragile, and more news to start your day.
Nov 18, 2025
The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company
Eli Lilly might soon join them for a far different reason: the weight-loss bonanza. This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker Novo Nordisk That is why investors shouldn’t assume the rally stops at a trillion. Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.
Nov 18, 2025
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It’s a Worry for the Stocks.
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Nov 18, 2025
Lilly Stock Continues Its Winning Ways
Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lilly inched closer to the $1 trillion market cap milestone.
Nov 18, 2025
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Nov 17, 2025
2 Mooning Stocks to Keep an Eye On and 1 We Ignore
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Nov 17, 2025
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Nov 17, 2025
How the Narrative Around Eli Lilly Is Evolving After New Analyst Updates and Drug Developments
Eli Lilly's stock has captured attention as consensus analyst price targets have risen from $919 to $1,003 per share. This shift underscores renewed optimism about the company's valuation prospects. The upward revision largely reflects analysts’ growing confidence in revenue growth, supported by robust demand for key treatments and steady execution across major franchises. As Wall Street continues to update its outlook in response to new data and market dynamics, readers will want to keep an...
Nov 17, 2025
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts
With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a $100 price target. The firm cited upcoming ACCESS I and II Phase 2b […]
Nov 17, 2025
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.
Nov 17, 2025
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration
Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.
Nov 17, 2025
This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000?
Healthcare stocks have far outperformed the broader market over the past month.
Nov 17, 2025
Eli Lilly Could Be Next Company to Split Its Stock
The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.
Nov 17, 2025
Novo Nordisk Cuts Prices for Obesity Drugs
The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the treatments between Nov. 17 and March 31.
Nov 17, 2025
Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point
This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.
Nov 17, 2025
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks?
Investors will be watching what Trump makes happen.
Nov 16, 2025
Prediction: This Will Be Wall Street's Next Trillion-Dollar Stock
Drugs for weight loss and diabetes are taking Eli Lilly to new heights.
Nov 16, 2025
Investing.com’s stocks of the week
Investing.com – The S&P 500 and Nasdaq are on track to close slightly higher this week, despite significant volatility.
Nov 15, 2025
Eli Lilly’s (LLY) “a Great Company,” Says Jim Cramer
We recently published 11 Stocks Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Cramer has again started to frequently discuss Eli Lilly and Company (NYSE:LLY) on his morning show. During the year’s first half, the CNBC TV host repeatedly praised the firm’s manufacturing initiatives and […]
Nov 15, 2025
Eli Lilly (LLY): Evaluating Valuation as Growth Momentum Builds
Eli Lilly (LLY) shares have shown steady momentum in recent weeks, not because of a single headline event, but rather due to investor focus on its long-term performance. The company’s growth has generated curiosity about its valuation. See our latest analysis for Eli Lilly. Momentum has clearly been building for Eli Lilly, with the share price climbing 24% over the last month and notching an impressive 38% total shareholder return for the year. Investors are paying attention to the company’s...
Nov 15, 2025
Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?
Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) dominates the search engine market with a greater than 90% share, powering billions of daily queries through Google Search. Yet its growth extends beyond that core business. Google Cloud has captured a rising slice of the cloud computing sector, trailing only Amazon (NASDAQ:AMZN) and Microsoft (NASDAQ:MSFT), while investments in artificial intelligence position it ... Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?
Nov 15, 2025
S&P 500 Posts Slight Weekly Rise, Led by Health Care, Energy
The Standard & Poor's 500 index edged up 0.1% this week as gains led by health care and energy stock
Nov 14, 2025
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Nov 14, 2025
Novo Chairman Blames Board Dropout on Former Employer Pfizer
The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.” “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said. Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.
Nov 14, 2025
Stocks to Watch Recap: Alphabet, Walmart, Eli Lilly, Warner Bros.
↗️ Alphabet (GOOGL): Warren Buffett’s Berkshire Hathaway added the Google parent company to its portfolio during the third quarter, according to a new disclosure late Friday. Alphabet shares rose 1.5% afterhours.
Nov 14, 2025
Eli Lilly Leads Three Stocks Near Buy Points
The stock market continued its sell-off Friday, but a few stocks ascended in buy zones and hovered near new highs. Eli Lilly, for one, hit an all-time high. Another is Valero, which has edged into a buy zone above an entry at 178.43, according to IBD MarketSurge.
Nov 14, 2025
Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock
Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05. Sometimes we see a divergence in share price and sentiment, but with Novo Nordisk they’re actually well correlated. Discussion on Reddit has remained uniformly bearish throughout November. Novo Nordisk is trading more than 50% ... Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock
Nov 14, 2025
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim
The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.
Nov 14, 2025
Raising the bar: can higher drug spending in the UK deliver for pharma and patients?
The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.
Nov 14, 2025
Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since
Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.
Nov 14, 2025

LLY Reviews

CodeAndCapital
Dec 30, 2025
$LLY If this stock were a superhero, it would be the one saving the day while making everyone feel better about their lives!
Buy
TickerTyrant
Dec 30, 2025
$LLY Just another overhyped pharma stock riding the wave of desperation.
Sell
MarginDagger
Dec 29, 2025
$LLY Known for its commitment to research and development, this pharmaceutical giant continues to push the boundaries of science. Its diverse portfolio and strong pipeline reinforce its position as a leader in the industry.
Buy
StockNova
Dec 28, 2025
$LLY Renowned for its commitment to innovation in the pharmaceutical industry, this company is continuously advancing in drug development. Their recent breakthroughs position them as a leader in improving health outcomes globally.
Buy
QuantKnight
Dec 28, 2025
$LLY In the fast-paced world of pharmaceuticals, breakthrough treatments are critical, but will this giant be able to fend off challengers? Patients are waiting, and so are investors. Time is of the essence!
Buy
CapitalCreep
Dec 28, 2025
$LLY Hope you're not allergic to disappointing results.
Sell
AlphaStriker
Dec 27, 2025
$LLY Pharmaceuticals: because who doesn't love overpriced medications?
Sell
MarketPulseX
Dec 27, 2025
$LLY As a leader in the pharmaceutical industry, this company continues to develop groundbreaking treatments that address critical health needs. Its robust research and pipeline reflect a strong commitment to improving patient lives.
Buy
WallStreetBandit
Dec 25, 2025
$LLY Dominating the market while others struggle to keep up.
Buy
TradeReckoner
Dec 25, 2025
$LLY Pushing pills while profits slip? How original.
Sell
FinTechNomad
Dec 25, 2025
$LLY In the pharma race, this giant faces unprecedented challenges. The pressure to innovate and deliver is immense—failure is simply not an option!
Sell
CryptoCobra
Dec 25, 2025
$LLY They're making the world a little sweeter, one prescription at a time. Just like my secret candy stash!
Buy
TradeFrenzy
Dec 24, 2025
$LLY Big pharma's latest gimmick, don’t hold your breath.
Sell
BullRunBoss
Dec 24, 2025
$LLY If this stock were a superhero, it would definitely have the power to heal your portfolio—but don’t expect it to wear a cape!
Buy
YieldVector
Dec 24, 2025
$LLY As competition heats up in the biotech arena, this giant must navigate a labyrinth of innovation and market pressures. Will they emerge victorious or be left behind?
Buy
SignalStriker
Dec 24, 2025
$LLY With every report, the stakes seem to rise higher! A slip-up here could mean disaster, yet the potential rewards are tantalizingly close. Can you stand the pressure?
Sell
TickerTrickster
Dec 23, 2025
$LLY This player stays in the ring, throwing punches like a champ.
Buy
RiskProtocol
Dec 22, 2025
$LLY In a landscape filled with fierce competition, how well can this giant innovate and sustain its momentum? The pressure is palpable, and the stakes are high!
Buy
OptionCipher
Dec 22, 2025
$LLY Amidst breakthroughs in pharmaceuticals, the clock is ticking for this giant. Will they lead the charge or fall behind in the race?
Buy
TickerTyrant
Dec 22, 2025
$LLY Overhyped and underperforming; where's the magic?
Sell
AlphaVandal
Dec 21, 2025
$LLY Once a giant, now just a shadow of its former self.
Sell
MarketSavage
Dec 21, 2025
$LLY Overhyped medications won't fix the glaring issues here.
Sell
MarketPulseX
Dec 21, 2025
$LLY This industry leader continues to drive innovation in pharmaceuticals, with a strong pipeline of potential breakthroughs. Its historical performance, combined with strategic acquisitions, enhances its competitive advantage.
Buy
TrendScript
Dec 21, 2025
$LLY A leader in pharmaceuticals, this corporation is at the forefront of research and development, particularly in critical therapies that address unmet medical needs. Its strong pipeline and commitment to innovation indicate a promising future in healthcare advancement.
Buy
AlphaRift
Dec 21, 2025
$LLY This well-established pharmaceuticals leader continues to push the envelope with groundbreaking research and development, particularly in critical therapeutic areas.
Buy
TraderFury
Dec 21, 2025
$LLY With groundbreaking treatments competing for attention, can they sustain their momentum and redefine patient care, or will emerging rivals steal the spotlight? The pressure to deliver is monumental!
Buy
BullishBard
Dec 20, 2025
$LLY Eli Lilly sounds like a character from a rom-com who always has the cure for heartbreak. Let’s see if their stock can heal wallets too!
Buy
FinTechFrost
Dec 20, 2025
$LLY Like your go-to superhero, this company always seems to swoop in and save the day with its products!
Buy
MarketNomad
Dec 20, 2025
$LLY If only this company delivered as well as its hype.
Sell
TheMemeInvestor
Dec 18, 2025
$LLY Straight fire, droppin' heat in the healthcare scene, keep your eyes peeled!
Buy
QuantRift
Dec 17, 2025
$LLY This pharmaceutical leader is at the forefront of groundbreaking research and development, particularly in the areas of diabetes and oncology. Its robust pipeline and focus on innovative therapies reflect a strong potential for impact in healthcare.
Buy
TheRiskDealer
Dec 17, 2025
$LLY The stakes are high with this one, and the pressure is palpable! With all the buzz, will it live up to the hype or leave you hanging? Keep your eyes peeled!
Buy
QuantKnight
Dec 15, 2025
$LLY With breakthroughs in pharmaceuticals on the table, this company's innovations are crucial—yet the competition is fierce! Every moment could change the game for them!
Buy
CapitalFrame
Dec 14, 2025
$LLY As a leading pharmaceutical company, its extensive pipeline and commitment to research and development position it favorably for addressing global health challenges and capturing market share.
Buy
WallStreetWolf
Dec 14, 2025
$LLY This one’s got the cure for boring stocks! It’s like the life of the party, but for your portfolio!
Buy
YOLOTrader
Dec 14, 2025
$LLY If this firm were a snack, it’d be the ‘healthy yet tasty’ kind—total game changer in the pantry of life!
Buy
MoneyMage
Dec 14, 2025
$LLY Sure, they have drugs, but they also have a price tag to match.
Sell
TheGainReaper
Dec 14, 2025
$LLY The hype is strong, but reality is a bitter pill.
Sell
BullRunBoss
Dec 13, 2025
$LLY Like the superhero of pharmaceuticals, this company swoops in to save the day! Forget capes, they wear lab coats and bring cures instead!
Buy
WallStreetWolf
Dec 13, 2025
$LLY This stock has more secrets than a teenage diary. Spoiler alert: it’s got some serious promise for the future!
Buy
BearEater
Dec 13, 2025
$LLY As a leader in biopharmaceuticals, this firm continues to push the boundaries of innovation with its pipeline of treatments. Its commitment to research and development could lead to significant breakthroughs.
Buy
MarketRender
Dec 13, 2025
$LLY Pharmaceutical breakthroughs can save lives, but the competition is fierce and the landscape is fraught! Is this giant on the verge of a breakthrough or a misstep? Tread carefully!
Buy
TheRiskDealer
Dec 13, 2025
$LLY Bullish volume spike caught my attention.
Buy
TradeNinja
Dec 13, 2025
$LLY This company's got the secret sauce for health—think of it as the cool kid at the wellness party everyone wants to hang out with!
Buy
QuantumBroker
Dec 13, 2025
$LLY The buzz surrounding this stock is palpable! It's like everyone is holding their breath, waiting for that pivotal moment that could change everything.
Buy
TradeMatrix
Dec 12, 2025
$LLY Positive market structure overall.
Buy
CodeTrader
Dec 12, 2025
$LLY Large buyers stepping in at every dip.
Buy
HODLzilla
Dec 12, 2025
$LLY Continuation pattern to downside.
Sell
DividendDegen
Dec 11, 2025
$LLY Bearish flow dominating options chain.
Sell
ChartFang
Dec 11, 2025
$LLY Bulls will likely push through resistance.
Buy
CashMeOutside
Dec 11, 2025
$LLY Downward drift not slowing.
Sell
BullRunBoi
Dec 11, 2025
$LLY Buyers not backing down.
Buy
ShortAndProud
Dec 10, 2025
$LLY This company’s got the meds that keep the game strong, no cap!
Buy
TradeNinja
Dec 10, 2025
$LLY This stock is like your favorite superhero — always saving the day, even when things get rough!
Buy
QuantumBroker
Dec 10, 2025
$LLY With the healthcare battlefield raging, this company is in the spotlight! Will they emerge victorious or get sidelined by new challengers that make you question everything?
Sell
SignalStriker
Dec 9, 2025
$LLY In the high-stakes pharmaceutical industry, delays in innovation can be catastrophic. The relentless pursuit of breakthroughs feels overwhelming, with lives hanging in the balance and competitors lurking!
Buy
DividendDemon
Dec 9, 2025
$LLY Downside volatility elevated.
Sell
PixelBroker
Dec 8, 2025
$LLY This company is like your favorite teacher—always dropping knowledge and maybe a few doughnuts. Who doesn’t love a sweet surprise?
Buy
RiskRanger
Dec 8, 2025
$LLY This company is like that friend who always brings snacks to the party—super reliable and a total lifesaver!
Buy
WallStreetRogue
Dec 7, 2025
$LLY Pharmaceuticals are a battlefield right now. Every breakthrough feels urgent, but with fierce competition looming, will this giant continue to innovate or falter?
Buy
TradeNova
Dec 6, 2025
$LLY Big Pharma flex, makin’ big moves in the health scene!
Buy
TrendHunter
Dec 6, 2025
$LLY Too much hype for just another drug in the crowded market.
Sell
FiscalFrost
Dec 5, 2025
$LLY This pharmaceutical leader continues to push boundaries with groundbreaking research and development. Its pipeline of innovative therapies demonstrates a strong commitment to addressing pressing healthcare challenges.
Buy
DividendDemon
Dec 5, 2025
$LLY This stock is like the secret ingredient in grandma's recipe – it just makes everything better and healthier!
Buy
QuantumBroker
Dec 4, 2025
$LLY Price action extremely fragile.
Sell
HoldTheLine
Dec 4, 2025
$LLY Lots of trapped longs unloading.
Sell
DigitalDividend
Dec 4, 2025
$LLY Bull flag pattern forming — looks promising.
Buy
CashClown
Dec 4, 2025
$LLY Bearish structure strengthening.
Sell
ManiaBroker
Dec 3, 2025
$LLY They've got more breakthroughs than my buddy has excuses for being late to class! 🚀
Buy
TradeMatrix
Dec 3, 2025
$LLY With groundbreaking advancements in pharmaceuticals, every moment counts! The pressure is on to stay ahead of the competition as new treatments flood the market. Can this company continue to lead the charge without losing momentum?
Buy
MemeInvestor
Dec 3, 2025
$LLY This company is like a magic potion for healthcare—just add a sprinkle of innovation and voila, life-saving solutions everywhere!
Buy
StonkSamurai
Dec 3, 2025
$LLY They’re flexing hard in the pharma game, no doubt!
Buy
VolatilityCore
Dec 3, 2025
$LLY The company continues to lead with groundbreaking research and development, addressing significant health challenges and expanding its therapeutic portfolio for greater impact.
Buy
FiscalFury
Dec 2, 2025
$LLY This stock is basically the superhero of the market—saving the day one investment at a time!
Buy
AlphaHawk
Dec 2, 2025
$LLY They’re making moves that matter, keep that in your sights!
Buy
TickerTakedown
Dec 2, 2025
$LLY This company is like your overachieving friend who aced every test. Impressive, but can it handle the pressure of adulting?
Buy
BullRunBandit
Dec 2, 2025
$LLY This one’s droppin' heat in the health scene, keep an eye on the action!
Buy
BullishCraze
Dec 1, 2025
$LLY This pharmaceutical leader continues to make significant strides in developing groundbreaking treatments that enhance patient care. With a strong pipeline of products and a commitment to innovation, it remains well-positioned in an industry that values research and development.
Buy
AlphaRogue
Dec 1, 2025
$LLY If this stock were a superhero, it would be the one saving the day with life-changing medicines, cape and all! Who knew healthcare could be so heroic?
Buy
CapitalRush
Nov 30, 2025
$LLY With a robust pipeline and innovative therapies making waves in critical health areas, this company continues to demonstrate its commitment to improving patient outcomes, creating a strong narrative for long-term growth.
Buy
ShortSqueezeX
Nov 30, 2025
$LLY They're out here making medicine like it's a magic potion—Harry Potter would be proud!
Buy
HedgeKnight
Nov 30, 2025
$LLY This company is like a superhero in lab coats, saving lives and making profits at the same time! Who knew science could be so cool?
Buy
TradeHex
Nov 30, 2025
$LLY Renowned for its commitment to research and development, this leader in the pharmaceutical industry is continuously advancing treatment options. Its strong pipeline and impactful therapies highlight its dedication to improving patient health.
Buy
StonkRider
Nov 29, 2025
$LLY This industry leader continues to push boundaries in pharmaceuticals, particularly in diabetes and oncology treatments. Their robust pipeline and strategic investments suggest a strong future potential.
Buy
TheChartCode
Nov 29, 2025
$LLY This company is turning the healthcare game up a notch. They're like the superhero of the stock world—cape not included!
Buy
TradeGoblin
Nov 29, 2025
$LLY This pharma's got the magic touch, making big moves.
Buy
GammaGrind
Nov 28, 2025
$LLY Droppin' meds that got folks feelin' right, big ups in health.
Buy
EarningsEcho
Nov 28, 2025
$LLY This company is basically the superhero of healthcare! They’re out here saving lives and making profits—talk about multitasking!
Buy
PaperHandsGone
Nov 28, 2025
$LLY Killing it in the pharma game, got the goods!
Buy
Stonks4Days
Nov 28, 2025
$LLY This giant's flexing hard, watch it take over the scene!
Buy
AlphaStriker
Nov 27, 2025
$LLY You’d think with all that hype, they’d actually deliver something interesting.
Sell
AlphaRift
Nov 27, 2025
$LLY Known for its extensive research and development efforts, this pharmaceutical giant is making significant contributions to healthcare advancements. Its rich history of innovation positions it as a leader in the industry.
Buy
BullishVanguard
Nov 27, 2025
$LLY Another overpriced pharma stock banking on hype. Watch your wallets!
Sell
PaperHandsGone
Nov 26, 2025
$LLY Pharma hustle is real, keep your ears to the streets on this!
Buy
ShortSavage
Nov 26, 2025
$LLY With the biotech sector in flux, this company's pipeline must deliver or face the music. The clock is ticking for game-changing results!
Sell
MarginBeast
Nov 25, 2025
$LLY Overhyped meds and overpriced shares, typical.
Sell
FinTechFrost
Nov 25, 2025
$LLY This company is like a magician - making health problems disappear faster than my homework on a Friday night!
Buy
WallStreetRogue
Nov 25, 2025
$LLY With groundbreaking treatments on the horizon and the market buzzing with excitement, the pressure is on to keep up. Will they deliver the goods or crumble under expectations?
Buy
LiquidLegend
Nov 25, 2025
$LLY Cooking up some health magic, but are they just a tad too magical for their own good?
Sell
StockShotz
Nov 23, 2025
$LLY Investing here is like having a secret recipe for success—everyone wants it, but only a few get to enjoy it!
Buy
YOLOTrader
Nov 23, 2025
$LLY The kind of company that makes you feel all warm and fuzzy inside, just like a cozy blanket!
Buy
ProfitFang
Nov 23, 2025
$LLY This company is making significant strides in pharmaceutical innovation, particularly with its recent breakthroughs in diabetes treatment. Its robust pipeline and strong market position indicate a promising future.
Buy
ManiaBroker
Nov 23, 2025
$LLY This company is like that friend who always shares their snacks—trustworthy and generous with its health solutions!
Buy
BullishBerserker
Nov 23, 2025
$LLY Every headline about breakthroughs and setbacks sends shockwaves through the market. Investors are left in a frenzy, wondering if the innovations will translate into stability or more chaos down the line.
Sell
TradeBlitz
Nov 23, 2025
$LLY Their medicine is like a magic potion; I’d trust them to cure my post-exam anxiety with just a single pill!
Buy
WallStreetHex
Nov 22, 2025
$LLY This pharmaceutical giant is at the forefront of medical advancements, boasting a pipeline filled with ground-breaking therapies. Their ongoing research efforts and strategic collaborations promise to enhance their market position.
Buy
BearEater
Nov 22, 2025
$LLY With a robust pipeline of breakthrough therapies, this pharmaceutical giant continues to set the standard in biotechnology. Their recent advancements in diabetes and oncology treatments demonstrate a strong commitment to improving patient outcomes.
Buy
TradeMatrix
Nov 22, 2025
$LLY Innovation in pharmaceuticals is a double-edged sword! They’re driving forward, but with competition heating up, will they stay ahead? It’s a tense game of survival out there!
Buy
TheStockKnight
Nov 22, 2025
$LLY Big pharma keeps cashing in while patients suffer.
Sell
YieldMyth
Nov 21, 2025
$LLY This heavyweight’s got the power to knock it out the park.
Buy
TradeBlaze
Nov 21, 2025
$LLY With a rich pipeline of pharmaceuticals and an unwavering commitment to research and development, this leading player continuously brings innovative solutions to market. Its proactive approach to healthcare challenges is commendable and reflects strong potential.
Buy
MarketMatrix
Nov 21, 2025
$LLY Cooking up meds like a chef in a kitchen, making sure we feel great while living our best lives. Recipe for success!
Buy
ShortSavage
Nov 21, 2025
$LLY The pharmaceutical landscape is filled with challenges, and this giant has its share of ups and downs. Can they navigate the regulatory storm and keep shareholders smiling amidst the chaos?
Buy
TheTradingVerse
Nov 20, 2025
$LLY Renowned for its groundbreaking pharmaceutical innovations, this firm is dedicated to addressing some of the world's most pressing health challenges with cutting-edge solutions.
Buy
OptionNomad
Nov 19, 2025
$LLY With groundbreaking developments coming out of their lab, the pressure is on! This company could change the game, but can they keep up the momentum amidst rising challenges and regulatory scrutiny?
Buy
OptionRogue
Nov 19, 2025
$LLY A leader in its field, this firm's commitment to groundbreaking research and development is commendable. Its pipeline of innovative therapies could significantly enhance its competitive edge and drive future revenue growth.
Buy
CryptoCobra
Nov 18, 2025
$LLY When your stocks are prescribed for happiness, it’s like having a doctor on speed dial. Just don’t forget to take your profits!
Buy
PnLPhantom
Nov 18, 2025
$LLY The race for pharmaceutical innovation is intense! With breakthroughs and market reactions intertwining, this company is in the spotlight. Will it emerge as a hero, or face backlash in the market?
Buy
TradePredator
Nov 17, 2025
$LLY Big pharma playing god with prices and ethics.
Sell
DividendGhost
Nov 17, 2025
$LLY In the high-stakes pharmaceutical arena, innovation is everything. Can this company continue to deliver breakthrough therapies, or will they be overtaken by the next big thing?
Buy
RiskProtocol
Nov 16, 2025
$LLY Amidst fierce competition and rising costs, this giant is feeling the heat. Every decision feels monumental, and investors are holding their breath to see if they can maintain their foothold in this cutthroat environment.
Sell
TradeReckoner
Nov 16, 2025
$LLY You call this innovation? It's more like a rehashed idea.
Sell
MarginBeast
Nov 14, 2025
$LLY Overhyped and overpriced, just like the meds.
Sell
EarningsEcho
Nov 14, 2025
$LLY If this stock were a superhero, it’d definitely have a cape made of prescriptions and a mission to save the day!
Buy
OptionOutlaw
Nov 13, 2025
$LLY Chasing trends instead of setting them.
Sell
DiamondHandz
Nov 13, 2025
$LLY Pharma kingpin flexing hard, keepin' it fresh and legit.
Buy
AlgoAce
Nov 12, 2025
$LLY Delivering medicines like pizza on a Friday night—hot, fresh, and always at your door (or pharmacy)!
Buy
TradeBlaze
Nov 12, 2025
$LLY Recent advancements in innovative therapies position this company at the forefront of the biotech sector, promising significant long-term benefits. With a strong pipeline and a focus on patient needs, it continues to lead in its field.
Buy
StonkViking
Nov 12, 2025
$LLY They’re makin’ waves in the health game, straight up fire!
Buy
ChartPilot
Nov 12, 2025
$LLY Amidst the urgent race for solutions in healthcare, this player could redefine success, yet the pressure from competitors and regulations could dim their light. Can they withstand the heat?
Buy
EarningsSync
Nov 11, 2025
$LLY With groundbreaking treatments at stake, the tension is palpable. Every breakthrough is met with skepticism and hope. How will they navigate the pressures of expectations?
Buy
StockShotz
Nov 9, 2025
$LLY This company's got more breakthroughs than my friend’s excuses for missing gym class!
Buy
HODLzilla
Nov 9, 2025
$LLY This joint is poppin' with that health hustle, makin' big waves, ya feel me?
Buy